Advertisement

Topics

'Keytruda is King' in lung cancer, putting BMS and next-gen in the shade

04:13 EDT 17 Apr 2018 | pharmaphorum

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly extended. Immunotherapy rivals BMS also presented ...

Original Article: 'Keytruda is King' in lung cancer, putting BMS and next-gen in the shade

NEXT ARTICLE

More From BioPortfolio on "'Keytruda is King' in lung cancer, putting BMS and next-gen in the shade"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...